BiodiversiTx -  Brazilian Biodiversity Therapeutics
Few tickets left

BiodiversiTx - Brazilian Biodiversity Therapeutics

Brazilian Biodiversity Therapeutics (BiodiversiTx)

By ABIQUIFI - Brazilian Industry Association of Active Pharmaceutical Ingredient

Date and time

Tuesday, June 4 · 1:30 - 3pm PDT

Location

Hilton San Diego Gaslamp Quarter

401 K Street San Diego, CA 92101

About this event

  • 1 hour 30 minutes

Venue: Hilton San Diego Gaslamp

Date: Tuesday, June 4th, 2024

Time: 1:30 PM to 3:00 PM


BiodiversiTx aims to discuss how biodiversity molecular crosstalk offers a solution for One Health. The session will delve into Brazil’s biopharmaceutical Brazilian National Innovation System and its unique position to sustainably utilize biodiversity as a platform to generate the next generation of therapeutics.

We anticipate 80 attendees, including companies and investors, to foster impactful partnerships and innovative initiatives.

The BiodiversiTx event aims to promote the scientific, technological, legal, regulatory, and business environment for the development of pharmaceuticals (both veterinary and human) sourced from Brazilian biodiversity, emphasizing its implications for local production and global commercialization.


1:00 PM – Welcoming

1:30 PM - Opening

  • Abiquifi – Brazilian Industry Association of Active Pharmaceutical Ingredient
  • Abifisa - Brazilian Association of Companies in the Phytotherapeutic, Food Supplement and Health Promotion Sector
  • ApexBrasil - Brazilian Trade and Investiment Promotion Agency
  • General Consulate of Brazil in Los Angeles

1:40 PM

  • Nascimento Mourão Law Firm
  • INPI - Brazilian National Institute of Industrial Property;
  • Biominas
  • Emerge Brasil
  • Ache Pharma
  • Centroflora Group
  • Nintx
  • Biolab Pharma
  • University of Sao Paulo
  • CNPEM -Brazilian Center for Research in Energy and Materials
  • Sthorm

3:00 PM - Closing

Target Audience:

80 professionals, including representatives from pharmaceutical companies, researchers, and private investors.